|1.||Markman, Maurie: 7 articles (01/2011 - 07/2003)|
|2.||Krediet, Raymond T: 3 articles (11/2011 - 12/2007)|
|3.||de Waart, Dirk R: 3 articles (11/2011 - 12/2007)|
|4.||Coester, Annemieke M: 3 articles (11/2011 - 12/2007)|
|5.||Bast, Robert C: 2 articles (01/2016 - 06/2010)|
|6.||Verheijen, René H M: 2 articles (01/2016 - 08/2002)|
|7.||D'Aloia, Antonio: 2 articles (01/2012 - 07/2003)|
|8.||Dei Cas, Livio: 2 articles (01/2012 - 07/2003)|
|9.||Smit, Watske: 2 articles (11/2011 - 12/2007)|
|10.||Struijk, Dirk G: 2 articles (11/2011 - 12/2007)|
05/01/2011 - "Screening strategies using ultrasound and the cancer antigen (CA) 125 tumor marker are currently under study and may lower stage at diagnosis but have not yet been shown to improve survival. "
02/01/1995 - "We compared the improved Abbott IMx cancer antigen (CA) 125 assay (cat. "
10/01/2015 - "Therefore, in this study we focused on human epididymis protein 4 and its contribution to the preoperative differentiation of prognostically distinct groups of patients and to individualized surgical treatment as compared with cancer antigen (CA) 125 and imaging methods. "
01/01/2009 - "The aim of this study was to assess the prognostic value of cancer antigen (CA) 125 and CA 72-4 in patients with ovarian borderline tumor (BOT). "
07/01/2006 - "This study also evaluated whether optimism predicted a decrease in cancer antigen (CA) 125 levels during treatment. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
01/01/1989 - "False positive results in an enzyme immunometric assay for the ovarian cancer associated antigen CA 125."
01/01/2003 - "Monoclonal antibody application in ovarian cancer started eight years after the discovery of Köhler and Milstein, with the studies of Bast et al. which led to the introduction of CA 125 antigen estimation to everyday clinical routine. "
01/01/1997 - "Two ovarian cancer cell lines, OVC432 and the newly established CVU4I, were used to study the effect of Taxal on cell growth and simultaneous CA 125 antigen expression. "
04/01/2009 - "There are limited data regarding unique clinical or laboratory features associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers (EOC), particularly the relationship between CA-125 antigen levels and prognosis. "
01/01/2009 - "Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen."
08/01/1990 - "Evaluation of combined TPA and CA 125 antigen results revealed a remarkable improvement in the positivity rate and a significant decrease (P less than 0.05) in the negativity rate of ovarian carcinomas as compared with the result of each one separately. "
08/01/1990 - "These findings provide complementary evidence for the previous results on the plasma levels of TPA and CA 125 antigen and suggest that specific combinations of tumour markers may be more effective for the diagnosis and monitoring of ovarian carcinomas, than the use of any single marker."
05/01/2004 - "The tumour associated CA-125 antigen is widely used in monitoring ovarian carcinoma. "
08/01/2002 - "CA 125 antigen was the most sensitive marker for ovarian carcinoma (81%). "
01/01/2002 - "Evaluation of serum levels of CA 125 antigen has been considered as useful in diagnosis and monitoring of some ovarian carcinomas. "
|4.||Endometrial Neoplasms (Endometrial Cancer)
12/01/1999 - "We investigated the clinical utility of the serum CA-125 antigen level, an established marker of response or progression in ovarian cancer, to serve as a indicator of these events in patients with this highly malignant subtype of endometrial cancer. "
03/28/1993 - "[Serologic monitoring of patients with endometrial carcinoma using ovarian carcinoma antigen (CA 125)]."
01/01/2014 - "Summary The study was conducted to determine whether preoperative serum levels of cancer antigen (CA) 125, CA15- 3, CA19-9, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) are associated clinicopathologically with poor prognostic parameters and adjuvant treatment requirements in women with pure endometrioid endometrial cancer (EEC). "
01/01/1997 - "Serum cancer antigen (CA) 125, CA15.3, CA19.9, carcinoembryonic antigen and tissue polypeptide antigen were analyzed in 100 normal subjects, 47 patients with benign gynaecological diseases and 97 patients with endometrial cancer. "
01/01/1988 - "The present study was undertaken to test the parallel detectability of ovarian cancer antigen CA 125 and gastrointestinal cancer antigen CA 19-9 in the sera of patients with malignant ovarian tumors, benign ovarian tumors, endometrial cancers, cervical cancers, colorectal cancers, and trophoblastic tumors and in early 1st-trimester pregnant as well as in healthy nonpregnant controls. "
01/01/2014 - "The aim of this study was to determine the relationship between the levels of tumour marker CA 125 antigen and pelvic tumour size, histopathological type, stage, bilateral status, ascites, type of surgery, and postoperative complications. "
01/01/2014 - "Statistical analysis, based on Fisher's exact test, showed that patients with pelvic mass who presented with either of bilateral involvement/ascites (p = 0.000), higher stage (p = 0.001), inability for complete resection (p = 0.000), or postoperative complications (p = 0.001) had significantly higher serum concentrations of CA 125 antigen. "
01/01/2000 - "The presence of ascites, increased serum CA 125 antigen level and the administration of fewer chemotherapy courses (6 versus 10) after primary surgery affects the earlier relapse of disease."
01/01/2000 - "In all those cases relapse occurred earlier than in patients without ascites, with normal CA 125 antigen levels and after ten courses of chemotherapy. "
01/01/2000 - "The statistical analysis showed a correlation between the presence of ascites, increased serum CA 125 antigen level, the administration of six chemotherapy courses and the time of recurrence. "
|4.||Biological Tumor Markers (Tumor Markers)
|5.||Ovarian epithelial cancer
|6.||Prostate-Specific Antigen (Semenogelase)
|7.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)
|8.||CA-19-9 Antigen (CA 19-9 Antigen)
|9.||squamous cell carcinoma-related antigen
|10.||Biological Markers (Surrogate Marker)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)
|4.||Continuous Ambulatory Peritoneal Dialysis (CAPD)